Alsymo Overview
- Year Founded
-
2022

- Status
-
Private
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
1
Alsymo General Information
Description
Operator of a drug development company intended to develop a drug for a rare, debilitating and fatal disease Pulmonary Arterial Hypertension. The company's patented active ingredient counters vascular remodeling, which is the thickening of the vessels responsible for increased blood pressure in the lungs, enabling the healthcare industry to access suitable drugs to cure Pulmonary Arterial Hypertension.
Contact Information
Corporate Office
- 63 Rue Gabriel Peri
- 94270 Le Kremlin-Bicêtre
- France
Corporate Office
- 63 Rue Gabriel Peri
- 94270 Le Kremlin-Bicêtre
- France
Alsymo Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Accelerator/Incubator | Completed | Startup | ||||
1. Accelerator/Incubator | 01-Jun-2023 | Completed | Startup |
Alsymo Investors (1)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
SATT Paris-Saclay | Accelerator/Incubator | Minority |
Alsymo FAQs
-
When was Alsymo founded?
Alsymo was founded in 2022.
-
Where is Alsymo headquartered?
Alsymo is headquartered in Le Kremlin-Bicêtre, France.
-
What industry is Alsymo in?
Alsymo’s primary industry is Biotechnology.
-
Is Alsymo a private or public company?
Alsymo is a Private company.
-
What is Alsymo’s current revenue?
The current revenue for Alsymo is
. -
How much funding has Alsymo raised over time?
Alsymo has raised $709K.
-
Who are Alsymo’s investors?
SATT Paris-Saclay has invested in Alsymo.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »